Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to doubt the long-term potential of this stock,

This was the stock's third consecutive day of gains.

Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain.

Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Toyota Motor Corporation (TM) and Vertex Pharmaceuticals Incorporated (VRTX), as well as two micro-cap stocks BK Technologies Corporation (BKTI) and Servotronics,

This was the stock's second consecutive day of gains.